Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2004 1
2005 4
2006 7
2007 8
2008 7
2009 11
2010 7
2011 2
2012 14
2013 17
2014 13
2015 19
2016 17
2017 28
2018 16
2019 12
2020 11
2021 11
2022 12
2023 10
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Results by year

Filters applied: . Clear all
Page 1
Pharmacology and pharmacokinetics of tazemetostat.
Orleni M, Beumer JH. Orleni M, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2024 May;93(5):509-517. doi: 10.1007/s00280-024-04658-4. Epub 2024 Mar 23. Cancer Chemother Pharmacol. 2024. PMID: 38520556 Review.
Mitigation of Fetal Irradiation Injury from Mid-Gestation Total Body Radiation with Mitochondrial-Targeted GS-Nitroxide JP4-039.
Wu YL, Christodoulou AG, Beumer JH, Rigatti LH, Fisher R, Ross M, Watkins S, Cortes DRE, Ruck C, Manzoor S, Wyman SK, Stapleton MC, Goetzman E, Bharathi S, Wipf P, Tan T, Eiseman JL, Christner SM, Guo J, Lo CWY, Epperly MW, Greenberger JS. Wu YL, et al. Among authors: beumer jh. bioRxiv [Preprint]. 2024 Feb 14:2024.02.13.580105. doi: 10.1101/2024.02.13.580105. bioRxiv. 2024. PMID: 38405696 Free PMC article. Preprint.
Tumor cell p38 inhibition to overcome immunotherapy resistance.
Luke JJ, Dadey RE, Augustin RC, Newman S, Singh KB, Doerfler R, Behr S, Lee P, Isett B, Deitrick C, Li A, Joy M, Reeder C, Smith K, Urban J, Sellitto L, Jelinek M, Christner SM, Beumer JH, Villaruz LC, Kulkarni A, Davar D, Poklepovic AS, Najjar Y, Zandberg DP, Soloff AC, Bruno TC, Vujanović L, Skinner HD, Ferris RL, Bao R. Luke JJ, et al. Among authors: beumer jh. Res Sq [Preprint]. 2023 Aug 19:rs.3.rs-3183496. doi: 10.21203/rs.3.rs-3183496/v1. Res Sq. 2023. PMID: 37645831 Free PMC article. Preprint.
Pharmacology and pharmacokinetics of elacestrant.
Beumer JH, Foldi J. Beumer JH, et al. Cancer Chemother Pharmacol. 2023 Aug;92(2):157-163. doi: 10.1007/s00280-023-04550-7. Epub 2023 Jun 14. Cancer Chemother Pharmacol. 2023. PMID: 37314500
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Morris MJ, Heller G, Hillman DW, Bobek O, Ryan C, Antonarakis ES, Bryce AH, Hahn O, Beltran H, Armstrong AJ, Schwartz L, Lewis LD, Beumer JH, Langevin B, McGary EC, Mehan PT, Goldkorn A, Roth BJ, Xiao H, Watt C, Taplin ME, Halabi S, Small EJ. Morris MJ, et al. Among authors: beumer jh. J Clin Oncol. 2023 Jun 20;41(18):3352-3362. doi: 10.1200/JCO.22.02394. Epub 2023 Mar 30. J Clin Oncol. 2023. PMID: 36996380 Clinical Trial.
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620).
Malhotra MK, Pahuja S, Kiesel BF, Appleman LJ, Ding F, Lin Y, Tawbi HA, Stoller RG, Lee JJ, Belani CP, Chen AP, Giranda VL, Shepherd SP, Emens LA, Ivy SP, Chu E, Beumer JH, Puhalla S. Malhotra MK, et al. Among authors: beumer jh. Breast Cancer Res Treat. 2023 Apr;198(3):487-498. doi: 10.1007/s10549-023-06889-0. Epub 2023 Feb 28. Breast Cancer Res Treat. 2023. PMID: 36853577 Free PMC article. Clinical Trial.
Evaluating the indotecan-neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions.
Beumer JH, Kennard BC, Holleran JL, Moore N, Zlott J, Miller BM, Kummar S, Chen A, Doroshow J, Park W, Gobburu J, Dunn A. Beumer JH, et al. Cancer Chemother Pharmacol. 2023 Mar;91(3):219-230. doi: 10.1007/s00280-023-04509-8. Epub 2023 Feb 23. Cancer Chemother Pharmacol. 2023. PMID: 36813886 Free PMC article.
Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expression.
Sugitani N, Vendetti FP, Cipriano AJ, Pandya P, Deppas JJ, Moiseeva TN, Schamus-Haynes S, Wang Y, Palmer D, Osmanbeyoglu HU, Bostwick A, Snyder NW, Gong YN, Aird KM, Delgoffe GM, Beumer JH, Bakkenist CJ. Sugitani N, et al. Among authors: beumer jh. Cell Rep. 2022 Sep 20;40(12):111371. doi: 10.1016/j.celrep.2022.111371. Cell Rep. 2022. PMID: 36130512 Free PMC article.
Modular Smart Molecules for PSMA-Targeted Chemotherapy.
Olatunji FP, Pun M, Herman JW, Romero O, Maniatopoulos M, Latoche JD, Parise RA, Guo J, Beumer JH, Anderson CJ, Berkman CE. Olatunji FP, et al. Among authors: beumer jh. Mol Cancer Ther. 2022 Nov 3;21(11):1701-1709. doi: 10.1158/1535-7163.MCT-22-0160. Mol Cancer Ther. 2022. PMID: 35999662 Free PMC article.
A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.
Manzo J, Puhalla S, Pahuja S, Ding F, Lin Y, Appleman L, Tawbi H, Stoller R, Lee JJ, Diergaarde B, Kiesel BF, Yu J, Tan AR, Belani CP, Chew H, Garcia AA, Morgan RJ, Wahner Hendrickson AE, Visscher DW, Hurley RM, Kaufmann SH, Swisher EM, Oesterreich S, Katz T, Ji J, Zhang Y, Parchment RE, Chen A, Duan W, Giranda V, Shepherd SP, Ivy SP, Chu E, Beumer JH; ETCTN-8282 study team. Manzo J, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2022 May;89(5):721-735. doi: 10.1007/s00280-022-04430-6. Epub 2022 Apr 18. Cancer Chemother Pharmacol. 2022. PMID: 35435472 Free PMC article. Clinical Trial.
ALDH1A1 Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper.
Mandell JB, Douglas N, Ukani V, Beumer JH, Guo J, Payne J, Newman R, Mancinelli L, Intini G, Anderson CJ, Watters R, Weiss K. Mandell JB, et al. Among authors: beumer jh. Sarcoma. 2022 Jan 28;2022:7157507. doi: 10.1155/2022/7157507. eCollection 2022. Sarcoma. 2022. PMID: 35125923 Free PMC article.
A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.
Tan AR, Chan N, Kiesel BF, Stein MN, Moss RA, Malhotra J, Aisner J, Shah M, Gounder M, Lin H, Kane MP, Lin Y, Ji J, Chen A, Beumer JH, Mehnert JM. Tan AR, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2022 Jan;89(1):49-58. doi: 10.1007/s00280-021-04350-x. Epub 2021 Oct 20. Cancer Chemother Pharmacol. 2022. PMID: 34669023 Free PMC article. Clinical Trial.
Precision Dosing of Targeted Therapies Is Ready for Prime Time.
Groenland SL, Verheijen RB, Joerger M, Mathijssen RHJ, Sparreboom A, Beijnen JH, Beumer JH, Steeghs N, Huitema ADR. Groenland SL, et al. Among authors: beumer jh. Clin Cancer Res. 2021 Dec 15;27(24):6644-6652. doi: 10.1158/1078-0432.CCR-20-4555. Epub 2021 Sep 21. Clin Cancer Res. 2021. PMID: 34548319 Free PMC article.
Quantitation of Cabozantinib in Human Plasma by LC-MS/MS.
Jones R, Holleran J, Parise RA, Rudek MA, Chan J, Wen Y, Gobburu J, Lewis LD, Beumer JH. Jones R, et al. Among authors: beumer jh. J Chromatogr Sci. 2022 Mar 23;60(3):274-279. doi: 10.1093/chromsci/bmab090. J Chromatogr Sci. 2022. PMID: 34240176 Free PMC article.
Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors.
Maguire WF, Schmitz JC, Scemama J, Czambel K, Lin Y, Green AG, Wu S, Lin H, Puhalla S, Rhee J, Stoller R, Tawbi H, Lee JJ, Wright JJ, Beumer JH, Chu E, Appleman LJ; ETCTN-9153 Study Team. Maguire WF, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2021 Oct;88(4):643-654. doi: 10.1007/s00280-021-04317-y. Epub 2021 Jun 23. Cancer Chemother Pharmacol. 2021. PMID: 34164713 Free PMC article. Clinical Trial.
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study.
Zivanovic O, Chi DS, Zhou Q, Iasonos A, Konner JA, Makker V, Grisham RN, Brown AK, Nerenstone S, Diaz JP, Schroeder ED, Langstraat CL, Paroder V, Lakhman Y, Soldan K, Su K, Gardner GJ, Andikyan V, Guo J, Jewell EL, Long Roche K, Troso-Sandoval T, Lichtman SM, Moukarzel LA, Dessources K, Abu-Rustum NR, Aghajanian C, Tew WP, Beumer J, Sonoda Y, O'Cearbhaill RE. Zivanovic O, et al. Among authors: beumer j. J Clin Oncol. 2021 Aug 10;39(23):2594-2604. doi: 10.1200/JCO.21.00605. Epub 2021 May 21. J Clin Oncol. 2021. PMID: 34019431 Free PMC article. Clinical Trial.
Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study.
Jacobs SA, Lee JJ, George TJ, Wade JL 3rd, Stella PJ, Wang D, Sama AR, Piette F, Pogue-Geile KL, Kim RS, Gavin PG, Lipchik C, Feng H, Wang Y, Finnigan M, Kiesel BF, Beumer JH, Wolmark N, Lucas PC, Allegra CJ, Srinivasan A. Jacobs SA, et al. Among authors: beumer jh. Clin Cancer Res. 2021 Mar 15;27(6):1612-1622. doi: 10.1158/1078-0432.CCR-20-1831. Epub 2020 Nov 17. Clin Cancer Res. 2021. PMID: 33203645 Free PMC article. Clinical Trial.
In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine.
Joshi A, Kiesel BF, Chaphekar N, Jones R, Guo J, Kunos CA, Taylor S, Chu E, Venkataramanan R, Beumer JH. Joshi A, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2020 Nov;86(5):633-640. doi: 10.1007/s00280-020-04154-5. Epub 2020 Sep 28. Cancer Chemother Pharmacol. 2020. PMID: 32989483 Free PMC article.
Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors.
Eads JR, Krishnamurthi SS, Saltzman J, Bokar JA, Savvides P, Meropol NJ, Gibbons J, Koon H, Sharma N, Rogers L, Pink JJ, Xu Y, Beumer JH, Riendeau J, Fu P, Gerson SL, Dowlati A. Eads JR, et al. Among authors: beumer jh. Invest New Drugs. 2021 Feb;39(1):142-151. doi: 10.1007/s10637-020-00962-x. Epub 2020 Jun 17. Invest New Drugs. 2021. PMID: 32556884 Free PMC article. Clinical Trial.
Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. Coyne GO', et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. Cancer Chemother Pharmacol. 2020. PMID: 32314030 Free PMC article. Clinical Trial.
Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up.
Pothuri B, Brodsky AL, Sparano JA, Blank SV, Kim M, Hershman DL, Tiersten A, Kiesel BF, Beumer JH, Liebes L, Muggia F. Pothuri B, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2020 Apr;85(4):741-751. doi: 10.1007/s00280-020-04030-2. Epub 2020 Feb 13. Cancer Chemother Pharmacol. 2020. PMID: 32055930 Free PMC article. Clinical Trial.
Editorial.
Beumer JH. Beumer JH. Cancer Chemother Pharmacol. 2020 Jan;85(1):1. doi: 10.1007/s00280-020-04032-0. Cancer Chemother Pharmacol. 2020. PMID: 31974653 No abstract available.
Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies.
Siddiqi T, Frankel P, Beumer JH, Kiesel BF, Christner S, Ruel C, Song JY, Chen R, Kelly KR, Ailawadhi S, Kaesberg P, Popplewell L, Puverel S, Piekarz R, Forman SJ, Newman EM. Siddiqi T, et al. Among authors: beumer jh. Leuk Lymphoma. 2020 Feb;61(2):309-317. doi: 10.1080/10428194.2019.1672052. Epub 2019 Oct 16. Leuk Lymphoma. 2020. PMID: 31617432 Free PMC article. Clinical Trial.
Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies.
Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS. Appleman LJ, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2019 Dec;84(6):1289-1301. doi: 10.1007/s00280-019-03960-w. Epub 2019 Sep 23. Cancer Chemother Pharmacol. 2019. PMID: 31549216 Free PMC article. Clinical Trial.
Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM. Luu T, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2019 Dec;84(6):1201-1208. doi: 10.1007/s00280-019-03955-7. Epub 2019 Sep 14. Cancer Chemother Pharmacol. 2019. PMID: 31522242 Free PMC article. Clinical Trial.
Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10.
Abraham J, Montero AJ, Jankowitz RC, Salkeni MA, Beumer JH, Kiesel BF, Piette F, Adamson LM, Nagy RJ, Lanman RB, Sperinde J, Huang W, Allegra CJ, Srinivasan A, Wang Y, Pogue-Geile KL, Lucas PC, Jacobs SA. Abraham J, et al. Among authors: beumer jh. J Clin Oncol. 2019 Oct 10;37(29):2601-2609. doi: 10.1200/JCO.19.00858. Epub 2019 Aug 23. J Clin Oncol. 2019. PMID: 31442103 Free PMC article. Clinical Trial.
A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP. Takebe N, et al. Among authors: beumer jh. Br J Clin Pharmacol. 2019 Nov;85(11):2499-2511. doi: 10.1111/bcp.14054. Epub 2019 Sep 4. Br J Clin Pharmacol. 2019. PMID: 31271459 Free PMC article. Clinical Trial.
Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon Production.
Ghosh A, Shao L, Sampath P, Zhao B, Patel NV, Zhu J, Behl B, Parise RA, Beumer JH, O'Sullivan RJ, DeLuca NA, Thorne SH, Rathinam VAK, Li P, Sarkar SN. Ghosh A, et al. Among authors: beumer jh. Immunity. 2019 Jan 15;50(1):51-63.e5. doi: 10.1016/j.immuni.2018.12.013. Epub 2019 Jan 8. Immunity. 2019. PMID: 30635239 Free PMC article.
Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.
Singh R, Mehrotra S, Gopalakrishnan M, Gojo I, Karp JE, Greer JM, Chen A, Piekarz R, Kiesel BF, Gobburu J, Rudek MA, Beumer JH; ETCTN-6745 study team. Singh R, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2019 Feb;83(2):319-328. doi: 10.1007/s00280-018-3731-4. Epub 2018 Nov 20. Cancer Chemother Pharmacol. 2019. PMID: 30456480 Free PMC article. Clinical Trial.
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y. Burton JH, et al. Among authors: beumer jh. Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30. Clin Cancer Res. 2018. PMID: 30061364 Free PMC article.
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation.
Vendetti FP, Karukonda P, Clump DA, Teo T, Lalonde R, Nugent K, Ballew M, Kiesel BF, Beumer JH, Sarkar SN, Conrads TP, O'Connor MJ, Ferris RL, Tran PT, Delgoffe GM, Bakkenist CJ. Vendetti FP, et al. Among authors: beumer jh. J Clin Invest. 2018 Aug 31;128(9):3926-3940. doi: 10.1172/JCI96519. Epub 2018 Aug 13. J Clin Invest. 2018. PMID: 29952768 Free PMC article.
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.
Beumer JH, Chu E, Allegra C, Tanigawara Y, Milano G, Diasio R, Kim TW, Mathijssen RH, Zhang L, Arnold D, Muneoka K, Boku N, Joerger M. Beumer JH, et al. Clin Pharmacol Ther. 2019 Mar;105(3):598-613. doi: 10.1002/cpt.1124. Epub 2018 Sep 11. Clin Pharmacol Ther. 2019. PMID: 29923599 Free PMC article. Review.
Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi.
Tahata S, Singh SV, Lin Y, Hahm ER, Beumer JH, Christner SM, Rao UN, Sander C, Tarhini AA, Tawbi H, Ferris LK, Wilson M, Rose A, Dietz CM, Hughes E, Fahey JW, Leachman SA, Cassidy PB, Butterfield LH, Zarour HM, Kirkwood JM. Tahata S, et al. Among authors: beumer jh. Cancer Prev Res (Phila). 2018 Jul;11(7):429-438. doi: 10.1158/1940-6207.CAPR-17-0268. Epub 2018 Apr 24. Cancer Prev Res (Phila). 2018. PMID: 29691233 Free PMC article. Clinical Trial.
A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia.
Redner RL, Beumer JH, Kropf P, Agha M, Boyiadzis M, Dorritie K, Farah R, Hou JZ, Im A, Lim SH, Raptis A, Sehgal A, Christner SM, Normolle D, Johnson DE. Redner RL, et al. Among authors: beumer jh. Leuk Lymphoma. 2018 Nov;59(11):2595-2601. doi: 10.1080/10428194.2018.1443330. Epub 2018 Apr 4. Leuk Lymphoma. 2018. PMID: 29616864 Free PMC article. Clinical Trial.
Targeting p53-dependent stem cell loss for intestinal chemoprotection.
Leibowitz BJ, Yang L, Wei L, Buchanan ME, Rachid M, Parise RA, Beumer JH, Eiseman JL, Schoen RE, Zhang L, Yu J. Leibowitz BJ, et al. Among authors: beumer jh. Sci Transl Med. 2018 Feb 7;10(427):eaam7610. doi: 10.1126/scitranslmed.aam7610. Sci Transl Med. 2018. PMID: 29437148 Free PMC article.
Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer.
Benoist GE, van der Meulen E, van Oort IM, Beumer JH, Somford DM, Schalken JA, Burger DM, van Erp NP. Benoist GE, et al. Among authors: beumer jh. Ther Drug Monit. 2018 Apr;40(2):222-229. doi: 10.1097/FTD.0000000000000484. Ther Drug Monit. 2018. PMID: 29419723 Free PMC article.
Erratum for Hoberman et al., "Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media".
Hoberman A, Paradise JL, Rockette HE, Jeong JH, Kearney DH, Bhatnagar S, Shope TR, Muñiz G, Martin JM, Kurs-Lasky M, Haralam M, Pope MA, Nagg JP, Zhao W, Miah MK, Beumer J, Venkataramanan R, Shaikh N. Hoberman A, et al. Among authors: beumer j. Antimicrob Agents Chemother. 2017 Dec 21;62(1):e02110-17. doi: 10.1128/AAC.02110-17. Print 2018 Jan. Antimicrob Agents Chemother. 2017. PMID: 29269433 Free PMC article. No abstract available.
Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma.
Christner S, Guo J, Parise RA, Ringeval M, Hoye AT, Wipf P, Epperly MW, Greenberger JS, Beumer JH, Eiseman JL. Christner S, et al. Among authors: beumer jh. J Pharm Biomed Anal. 2018 Feb 20;150:169-175. doi: 10.1016/j.jpba.2017.12.023. Epub 2017 Dec 12. J Pharm Biomed Anal. 2018. PMID: 29245086 Free PMC article.
Improving Carboplatin Dosing Based on Estimated GFR.
Beumer JH, Inker LA, Levey AS. Beumer JH, et al. Am J Kidney Dis. 2018 Feb;71(2):163-165. doi: 10.1053/j.ajkd.2017.10.005. Epub 2017 Dec 6. Am J Kidney Dis. 2018. PMID: 29217306 Free PMC article. No abstract available.
Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.
Chen GL, Carpenter PA, Broady R, Gregory TK, Johnston LJ, Storer BE, Beumer JH, Qiu J, Cerda K, Le R, Otani JM, Liu H, Ross MA, Arai S, Flowers MED, McCarthy PL, Miklos DB. Chen GL, et al. Among authors: beumer jh. Biol Blood Marrow Transplant. 2018 Feb;24(2):373-380. doi: 10.1016/j.bbmt.2017.10.021. Epub 2017 Oct 16. Biol Blood Marrow Transplant. 2018. PMID: 29051021 Free PMC article. Clinical Trial.
Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer.
Luu T, Kim KP, Blanchard S, Anyang B, Hurria A, Yang L, Beumer JH, Somlo G, Yen Y. Luu T, et al. Among authors: beumer jh. Breast Cancer Res Treat. 2018 Jan;167(2):469-478. doi: 10.1007/s10549-017-4516-x. Epub 2017 Sep 27. Breast Cancer Res Treat. 2018. PMID: 28956187 Clinical Trial.
Phase I study of veliparib in combination with gemcitabine.
Stoller R, Schmitz JC, Ding F, Puhalla S, Belani CP, Appleman L, Lin Y, Jiang Y, Almokadem S, Petro D, Holleran J, Kiesel BF, Ken Czambel R, Carneiro BA, Kontopodis E, Hershberger PA, Rachid M, Chen A, Chu E, Beumer JH. Stoller R, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2017 Sep;80(3):631-643. doi: 10.1007/s00280-017-3409-3. Epub 2017 Aug 2. Cancer Chemother Pharmacol. 2017. PMID: 28770300 Free PMC article. Clinical Trial.
Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media.
Hoberman A, Paradise JL, Rockette HE, Jeong JH, Kearney DH, Bhatnagar S, Shope TR, Muñiz G, Martin JM, Kurs-Lasky M, Haralam M, Pope MA, Nagg JP, Zhao W, Miah MK, Beumer J, Venkataramanan R, Shaikh N. Hoberman A, et al. Among authors: beumer j. Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00238-17. doi: 10.1128/AAC.00238-17. Print 2017 Jul. Antimicrob Agents Chemother. 2017. PMID: 28438923 Free PMC article. Clinical Trial.
Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types.
Niu J, Scheuerell C, Mehrotra S, Karan S, Puhalla S, Kiesel BF, Ji J, Chu E, Gopalakrishnan M, Ivaturi V, Gobburu J, Beumer JH. Niu J, et al. Among authors: beumer jh. J Clin Pharmacol. 2017 Aug;57(8):977-987. doi: 10.1002/jcph.892. Epub 2017 Apr 7. J Clin Pharmacol. 2017. PMID: 28387939 Free PMC article. Clinical Trial.
Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma.
Benoist GE, van der Meulen E, Lubberman FJE, Gerritsen WR, Smilde TJ, Schalken JA, Beumer JH, Burger DM, van Erp NP. Benoist GE, et al. Among authors: beumer jh. Biomed Chromatogr. 2017 Nov;31(11):10.1002/bmc.3986. doi: 10.1002/bmc.3986. Epub 2017 May 16. Biomed Chromatogr. 2017. PMID: 28370076 Free PMC article.
Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083.
Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. Somlo G, et al. Among authors: beumer jh. Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29. Clin Cancer Res. 2017. PMID: 28356425 Free PMC article. Clinical Trial.
A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Jandial DA, Brady WE, Howell SB, Lankes HA, Schilder RJ, Beumer JH, Christner SM, Strychor S, Powell MA, Hagemann AR, Moore KN, Walker JL, DiSilvestro PA, Duska LR, Fracasso PM, Dizon DS. Jandial DA, et al. Among authors: beumer jh. Gynecol Oncol. 2017 May;145(2):236-242. doi: 10.1016/j.ygyno.2017.03.013. Epub 2017 Mar 22. Gynecol Oncol. 2017. PMID: 28341300 Free PMC article. Clinical Trial.
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.
Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA Jr, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. Soumerai JD, et al. Among authors: beumer jh. Clin Cancer Res. 2017 Aug 1;23(15):4119-4126. doi: 10.1158/1078-0432.CCR-16-3068. Epub 2017 Mar 17. Clin Cancer Res. 2017. PMID: 28314788 Free PMC article. Clinical Trial.
A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study.
Rader JS, Sill MW, Beumer JH, Lankes HA, Benbrook DM, Garcia F, Trimble C, Tate Thigpen J, Lieberman R, Zuna RE, Leath CA 3rd, Spirtos NM, Byron J, Thaker PH, Lele S, Alberts D. Rader JS, et al. Among authors: beumer jh. Gynecol Oncol. 2017 May;145(2):291-297. doi: 10.1016/j.ygyno.2017.02.040. Epub 2017 Mar 10. Gynecol Oncol. 2017. PMID: 28285845 Free PMC article. Clinical Trial.
Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study.
von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. von Gruenigen VE, et al. Among authors: beumer jh. Gynecol Oncol. 2017 Mar;144(3):459-467. doi: 10.1016/j.ygyno.2016.11.033. Epub 2017 Jan 13. Gynecol Oncol. 2017. PMID: 28089376 Free PMC article.
A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.
Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE. Gojo I, et al. Among authors: beumer jh. Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8. Clin Cancer Res. 2017. PMID: 27503200 Free PMC article. Clinical Trial.
Therapeutic drug monitoring of 5-fluorouracil.
Lee JJ, Beumer JH, Chu E. Lee JJ, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2016 Sep;78(3):447-64. doi: 10.1007/s00280-016-3054-2. Epub 2016 May 23. Cancer Chemother Pharmacol. 2016. PMID: 27217046 Free PMC article. Review.
Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.
Kummar S, Chen A, Gutierrez M, Pfister TD, Wang L, Redon C, Bonner WM, Yutzy W, Zhang Y, Kinders RJ, Ji J, Allen D, Covey JM, Eiseman JL, Holleran JL, Beumer JH, Rubinstein L, Collins J, Tomaszewski J, Parchment R, Pommier Y, Doroshow JH. Kummar S, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2016 Jul;78(1):73-81. doi: 10.1007/s00280-016-2998-6. Epub 2016 May 11. Cancer Chemother Pharmacol. 2016. PMID: 27169793 Free PMC article. Clinical Trial.
Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET, Kurland BF, Griffin M, Gralow JR, Porter P, Yeh RF, Gadi VK, Guenthoer J, Beumer JH, Korde L, Strychor S, Kiesel BF, Linden HM, Thompson JA, Swisher E, Chai X, Shepherd S, Giranda V, Specht JM. Rodler ET, et al. Among authors: beumer jh. Clin Cancer Res. 2016 Jun 15;22(12):2855-64. doi: 10.1158/1078-0432.CCR-15-2137. Epub 2016 Jan 22. Clin Cancer Res. 2016. PMID: 26801247 Free PMC article. Clinical Trial.
Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.
Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulkner T, Parise RA, Fawcett P, Pollice L, Mason S, Hague J, Croft M, Nugteren J, Tedder C, Sun W, Chu E, Beumer JH. Lee JJ, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2016 Mar;77(3):515-26. doi: 10.1007/s00280-016-2965-2. Epub 2016 Jan 19. Cancer Chemother Pharmacol. 2016. PMID: 26787503 Free PMC article. Clinical Trial.
ATM serine-1981 phosphorylation is a plausible biomarker.
Bakkenist CJ, Beumer JH, Schmitz JC. Bakkenist CJ, et al. Among authors: beumer jh. Cell Cycle. 2015;14(20):3207-8. doi: 10.1080/15384101.2015.1084205. Cell Cycle. 2015. PMID: 26517194 Free PMC article. No abstract available.
Blocking the ZZ domain of sequestosome1/p62 suppresses myeloma growth and osteoclast formation in vitro and induces dramatic bone formation in myeloma-bearing bones in vivo.
Teramachi J, Silbermann R, Yang P, Zhao W, Mohammad KS, Guo J, Anderson JL, Zhou D, Feng R, Myint KZ, Maertz N, Beumer JH, Eiseman JL, Windle JJ, Xie XQ, Roodman GD, Kurihara N. Teramachi J, et al. Among authors: beumer jh. Leukemia. 2016 Feb;30(2):390-8. doi: 10.1038/leu.2015.229. Epub 2015 Aug 19. Leukemia. 2016. PMID: 26286116 Free PMC article.
Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma.
Lee DH, Zhang Y, Kassam AB, Park MJ, Gardner P, Prevedello D, Henry S, Horbinski C, Beumer JH, Tawbi H, Williams BJ, Shaffrey ME, Egorin MJ, Abounader R, Park DM. Lee DH, et al. Among authors: beumer jh. PLoS One. 2015 Aug 6;10(8):e0134426. doi: 10.1371/journal.pone.0134426. eCollection 2015. PLoS One. 2015. PMID: 26247786 Free PMC article.
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine.
Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry AB, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. Newman EM, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2015 Mar;75(3):537-46. doi: 10.1007/s00280-014-2674-7. Epub 2015 Jan 8. Cancer Chemother Pharmacol. 2015. PMID: 25567350 Free PMC article. Clinical Trial.
A phase i study of DMS612, a novel bifunctional alkylating agent.
Appleman LJ, Balasubramaniam S, Parise RA, Bryla C, Redon CE, Nakamura AJ, Bonner WM, Wright JJ, Piekarz R, Kohler DR, Jiang Y, Belani CP, Eiseman J, Chu E, Beumer JH, Bates SE. Appleman LJ, et al. Among authors: beumer jh. Clin Cancer Res. 2015 Feb 15;21(4):721-9. doi: 10.1158/1078-0432.CCR-14-1333. Epub 2014 Dec 2. Clin Cancer Res. 2015. PMID: 25467180 Free PMC article. Clinical Trial.
Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).
Beumer JH, Owzar K, Lewis LD, Jiang C, Holleran JL, Christner SM, Blum W, Devine S, Kolitz JE, Linker C, Vij R, Alyea EP, Larson RA, Ratain MJ, Egorin MJ. Beumer JH, et al. Cancer Chemother Pharmacol. 2014 Nov;74(5):927-38. doi: 10.1007/s00280-014-2571-0. Epub 2014 Aug 28. Cancer Chemother Pharmacol. 2014. PMID: 25163570 Free PMC article. Clinical Trial.
Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
Owonikoko TK, Zhang G, Deng X, Rossi MR, Switchenko JM, Doho GH, Chen Z, Kim S, Strychor S, Christner SM, Beumer J, Li C, Yue P, Chen A, Sica GL, Ramalingam SS, Kowalski J, Khuri FR, Sun SY. Owonikoko TK, et al. Among authors: beumer j. Cancer Med. 2014 Dec;3(6):1579-94. doi: 10.1002/cam4.317. Epub 2014 Aug 13. Cancer Med. 2014. PMID: 25124282 Free PMC article.
Pharmacotherapy in cancer patients with HIV/AIDS.
Beumer JH, Venkataramanan R, Rudek MA. Beumer JH, et al. Clin Pharmacol Ther. 2014 Apr;95(4):370-2. doi: 10.1038/clpt.2014.10. Epub 2014 Jan 17. Clin Pharmacol Ther. 2014. PMID: 24440966 Free PMC article.
Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
Choi SW, Braun T, Chang L, Ferrara JL, Pawarode A, Magenau JM, Hou G, Beumer JH, Levine JE, Goldstein S, Couriel DR, Stockerl-Goldstein K, Krijanovski OI, Kitko C, Yanik GA, Lehmann MH, Tawara I, Sun Y, Paczesny S, Mapara MY, Dinarello CA, DiPersio JF, Reddy P. Choi SW, et al. Among authors: beumer jh. Lancet Oncol. 2014 Jan;15(1):87-95. doi: 10.1016/S1470-2045(13)70512-6. Epub 2013 Nov 30. Lancet Oncol. 2014. PMID: 24295572 Free PMC article. Clinical Trial.
Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers.
Tawbi H, Christner SM, Lin Y, Johnson M, Mowrey ET, Cherrin C, Chu E, Lee JJ, Puhalla S, Stoller R, Appleman LR, Miller BM, Beumer JH. Tawbi H, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2014 Jan;73(1):207-11. doi: 10.1007/s00280-013-2337-0. Epub 2013 Oct 30. Cancer Chemother Pharmacol. 2014. PMID: 24170263 Free PMC article. Clinical Trial.
Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice.
Parise RA, Beumer JH, Clausen DM, Rigatti LH, Ziegler JA, Gasparetto M, Smith CA, Eiseman JL. Parise RA, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2013 Dec;72(6):1195-204. doi: 10.1007/s00280-013-2296-5. Epub 2013 Sep 24. Cancer Chemother Pharmacol. 2013. PMID: 24061865 Free PMC article.
Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers.
Tawbi HA, Tran AL, Christner SM, Lin Y, Johnson M, Mowrey E, Appleman LR, Stoller R, Miller BM, Egorin MJ, Beumer JH. Tawbi HA, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2013 Nov;72(5):1143-7. doi: 10.1007/s00280-013-2283-x. Epub 2013 Sep 14. Cancer Chemother Pharmacol. 2013. PMID: 24036846 Free PMC article. Clinical Trial.
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK. Kelley RK, et al. Among authors: beumer jh. Br J Cancer. 2013 Oct 1;109(7):1725-34. doi: 10.1038/bjc.2013.553. Epub 2013 Sep 10. Br J Cancer. 2013. PMID: 24022191 Free PMC article. Clinical Trial.
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Pillai VC, Venkataramanan R, Parise RA, Christner SM, Gramignoli R, Strom SC, Rudek MA, Beumer JH. Pillai VC, et al. Among authors: beumer jh. Drug Metab Dispos. 2013 Oct;41(10):1843-51. doi: 10.1124/dmd.113.052100. Epub 2013 Aug 2. Drug Metab Dispos. 2013. PMID: 23913028 Free PMC article.
Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
Ma T, Galimberti F, Erkmen CP, Memoli V, Chinyengetere F, Sempere L, Beumer JH, Anyang BN, Nugent W, Johnstone D, Tsongalis GJ, Kurie JM, Li H, Direnzo J, Guo Y, Freemantle SJ, Dragnev KH, Dmitrovsky E. Ma T, et al. Among authors: beumer jh. Mol Cancer Ther. 2013 Aug;12(8):1545-55. doi: 10.1158/1535-7163.MCT-12-0933. Epub 2013 May 16. Mol Cancer Ther. 2013. PMID: 23686769 Free PMC article.
A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer.
Magge D, Zureikat AH, Bartlett DL, Holtzman MP, Choudry HA, Beumer JH, Pingpank JF, Holleran JL, Strychor S, Cunningham DE, Jones HL, Zeh HJ 3rd. Magge D, et al. Among authors: beumer jh. Ann Surg Oncol. 2013 Jul;20(7):2180-7. doi: 10.1245/s10434-013-2960-3. Epub 2013 Apr 11. Ann Surg Oncol. 2013. PMID: 23575907 Free PMC article. Clinical Trial.
Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Gojo I, Tan M, Fang HB, Sadowska M, Lapidus R, Baer MR, Carrier F, Beumer JH, Anyang BN, Srivastava RK, Espinoza-Delgado I, Ross DD. Gojo I, et al. Among authors: beumer jh. Clin Cancer Res. 2013 Apr 1;19(7):1838-51. doi: 10.1158/1078-0432.CCR-12-3165. Epub 2013 Feb 12. Clin Cancer Res. 2013. PMID: 23403629 Free PMC article. Clinical Trial.
In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts.
Guo J, Clausen DM, Beumer JH, Parise RA, Egorin MJ, Bravo-Altamirano K, Wipf P, Sharlow ER, Wang QJ, Eiseman JL. Guo J, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2013 Feb;71(2):331-44. doi: 10.1007/s00280-012-2010-z. Epub 2012 Oct 30. Cancer Chemother Pharmacol. 2013. PMID: 23108699 Free PMC article.
A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
Pishvaian MJ, Slack R, Koh EY, Beumer JH, Hartley ML, Cotarla I, Deeken J, He AR, Hwang J, Malik S, Firozvi K, Liu M, Elston B, Strychor S, Egorin MJ, Marshall JL. Pishvaian MJ, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2012 Dec;70(6):843-53. doi: 10.1007/s00280-012-1969-9. Epub 2012 Sep 27. Cancer Chemother Pharmacol. 2012. PMID: 23014737 Free PMC article. Clinical Trial.
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
Nabhan C, Villines D, Valdez TV, Tolzien K, Lestingi TM, Bitran JD, Christner SM, Egorin MJ, Beumer JH. Nabhan C, et al. Among authors: beumer jh. Br J Cancer. 2012 Aug 7;107(4):592-7. doi: 10.1038/bjc.2012.312. Epub 2012 Jul 17. Br J Cancer. 2012. PMID: 22805325 Free PMC article. Clinical Trial.
Role of PARP inhibitors in cancer biology and therapy.
Davar D, Beumer JH, Hamieh L, Tawbi H. Davar D, et al. Among authors: beumer jh. Curr Med Chem. 2012;19(23):3907-21. doi: 10.2174/092986712802002464. Curr Med Chem. 2012. PMID: 22788767 Free PMC article. Review.
Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Pietanza MC, Gadgeel SM, Dowlati A, Lynch TJ, Salgia R, Rowland KM Jr, Wertheim MS, Price KA, Riely GJ, Azzoli CG, Miller VA, Krug LM, Kris MG, Beumer JH, Tonda M, Mitchell B, Rizvi NA. Pietanza MC, et al. Among authors: beumer jh. J Thorac Oncol. 2012 May;7(5):856-65. doi: 10.1097/JTO.0b013e31824c943f. J Thorac Oncol. 2012. PMID: 22722787 Free article. Clinical Trial.
Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies.
Bose P, Perkins EB, Honeycut C, Wellons MD, Stefan T, Jacobberger JW, Kontopodis E, Beumer JH, Egorin MJ, Imamura CK, Douglas Figg W Sr, Karp JE, Koc ON, Cooper BW, Luger SM, Colevas AD, Roberts JD, Grant S. Bose P, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2012 Jun;69(6):1657-67. doi: 10.1007/s00280-012-1839-5. Epub 2012 Feb 15. Cancer Chemother Pharmacol. 2012. PMID: 22349810 Free PMC article. Clinical Trial.
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas.
Kummar S, Ji J, Morgan R, Lenz HJ, Puhalla SL, Belani CP, Gandara DR, Allen D, Kiesel B, Beumer JH, Newman EM, Rubinstein L, Chen A, Zhang Y, Wang L, Kinders RJ, Parchment RE, Tomaszewski JE, Doroshow JH. Kummar S, et al. Among authors: beumer jh. Clin Cancer Res. 2012 Mar 15;18(6):1726-34. doi: 10.1158/1078-0432.CCR-11-2821. Epub 2012 Feb 3. Clin Cancer Res. 2012. PMID: 22307137 Free PMC article. Clinical Trial.
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
Ramalingam SS, Kummar S, Sarantopoulos J, Shibata S, LoRusso P, Yerk M, Holleran J, Lin Y, Beumer JH, Harvey RD, Ivy SP, Belani CP, Egorin MJ. Ramalingam SS, et al. Among authors: beumer jh. J Clin Oncol. 2010 Oct 10;28(29):4507-12. doi: 10.1200/JCO.2010.30.2307. Epub 2010 Sep 13. J Clin Oncol. 2010. PMID: 20837947 Free PMC article. Clinical Trial.
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.
Beumer JH, Eiseman JL, Gilbert JA, Holleran JL, Yellow-Duke AE, Clausen DM, D'Argenio DZ, Ames MM, Hershberger PA, Parise RA, Bai L, Covey JM, Egorin MJ. Beumer JH, et al. Cancer Chemother Pharmacol. 2011 Feb;67(2):421-30. doi: 10.1007/s00280-010-1337-6. Epub 2010 May 5. Cancer Chemother Pharmacol. 2011. PMID: 20443002 Free PMC article.
Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.
Holleran JL, Parise RA, Yellow-Duke AE, Egorin MJ, Eiseman JL, Covey JM, Beumer JH. Holleran JL, et al. Among authors: beumer jh. J Pharm Biomed Anal. 2010 Sep 5;52(5):714-20. doi: 10.1016/j.jpba.2010.02.020. Epub 2010 Feb 23. J Pharm Biomed Anal. 2010. PMID: 20236781 Free PMC article.
Effect of a proton pump inhibitor on the pharmacokinetics of imatinib.
Egorin MJ, Shah DD, Christner SM, Yerk MA, Komazec KA, Appleman LR, Redner RL, Miller BM, Beumer JH. Egorin MJ, et al. Among authors: beumer jh. Br J Clin Pharmacol. 2009 Sep;68(3):370-4. doi: 10.1111/j.1365-2125.2009.03466.x. Br J Clin Pharmacol. 2009. PMID: 19740393 Free PMC article. Clinical Trial.
A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum.
Parise RA, Egorin MJ, Christner SM, Shah DD, Zhou W, Beumer JH. Parise RA, et al. Among authors: beumer jh. J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jul 1;877(20-21):1894-900. doi: 10.1016/j.jchromb.2009.05.034. Epub 2009 May 21. J Chromatogr B Analyt Technol Biomed Life Sci. 2009. PMID: 19493708 Free PMC article.
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Reardon DA, Egorin MJ, Desjardins A, Vredenburgh JJ, Beumer JH, Lagattuta TF, Gururangan S, Herndon JE 2nd, Salvado AJ, Friedman HS. Reardon DA, et al. Among authors: beumer jh. Cancer. 2009 May 15;115(10):2188-98. doi: 10.1002/cncr.24213. Cancer. 2009. PMID: 19248046 Free PMC article. Clinical Trial.
Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells.
Singh SV, Warin R, Xiao D, Powolny AA, Stan SD, Arlotti JA, Zeng Y, Hahm ER, Marynowski SW, Bommareddy A, Desai D, Amin S, Parise RA, Beumer JH, Chambers WH. Singh SV, et al. Among authors: beumer jh. Cancer Res. 2009 Mar 1;69(5):2117-25. doi: 10.1158/0008-5472.CAN-08-3502. Epub 2009 Feb 17. Cancer Res. 2009. PMID: 19223537 Free PMC article.
Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase.
Parise RA, Shawaqfeh M, Egorin MJ, Beumer JH. Parise RA, et al. Among authors: beumer jh. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Sep 1;872(1-2):141-7. doi: 10.1016/j.jchromb.2008.07.032. Epub 2008 Jul 31. J Chromatogr B Analyt Technol Biomed Life Sci. 2008. PMID: 18692448 Free PMC article.
Effect of antacid on imatinib absorption.
Sparano BA, Egorin MJ, Parise RA, Walters J, Komazec KA, Redner RL, Beumer JH. Sparano BA, et al. Among authors: beumer jh. Cancer Chemother Pharmacol. 2009 Feb;63(3):525-8. doi: 10.1007/s00280-008-0778-7. Epub 2008 May 24. Cancer Chemother Pharmacol. 2009. PMID: 18500518 Free PMC article. Clinical Trial.
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma.
Parise RA, Beumer JH, Kangani CO, Holleran JL, Eiseman JL, Smith NF, Covey JM, Perrine SP, Egorin MJ. Parise RA, et al. Among authors: beumer jh. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 1;862(1-2):168-74. doi: 10.1016/j.jchromb.2007.12.002. Epub 2007 Dec 8. J Chromatogr B Analyt Technol Biomed Life Sci. 2008. PMID: 18155649 Free PMC article.
Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Beumer JH, Rademaker-Lakhai JM, Rosing H, Hillebrand MJ, Bosch TM, Lopez-Lazaro L, Schellens JH, Beijnen JH. Beumer JH, et al. Cancer Chemother Pharmacol. 2007 May;59(6):825-37. doi: 10.1007/s00280-006-0342-2. Epub 2006 Sep 20. Cancer Chemother Pharmacol. 2007. PMID: 16988825
A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum.
Parise RA, Holleran JL, Beumer JH, Ramalingam S, Egorin MJ. Parise RA, et al. Among authors: beumer jh. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Aug 18;840(2):108-15. doi: 10.1016/j.jchromb.2006.04.044. Epub 2006 May 24. J Chromatogr B Analyt Technol Biomed Life Sci. 2006. PMID: 16725386
Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection.
Beumer JH, Joseph E, Egorin MJ, Covey JM, Eiseman JL. Beumer JH, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):147-55. doi: 10.1016/j.jchromb.2005.11.048. Epub 2005 Dec 20. J Chromatogr B Analyt Technol Biomed Life Sci. 2006. PMID: 16364698
Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Beumer JH, Rosing H, Hillebrand MJ, Nan-Offeringa LG, Foley K, Yule SM, Heck AJ, Schellens JH, Beijnen JH. Beumer JH, et al. Rapid Commun Mass Spectrom. 2004;18(23):2839-48. doi: 10.1002/rcm.1699. Rapid Commun Mass Spectrom. 2004. PMID: 15517526